Related Experiment Video
Updated: Apr 1, 2026
09:31
Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
7.8K
Smart approaches to glucose-responsive drug delivery
Matthew J Webber1,2, Daniel G Anderson1,2,3,4,5
1a David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge , MA , USA .
Journal of Drug Targeting
|October 11, 2015
Summary
Developing a fully synthetic pancreas for diabetes involves creating glucose-sensing insulin delivery systems. Challenges remain in response time, control fidelity, and material biocompatibility for effective closed-loop therapy.
Area of Science:
- Biomedical Engineering
- Materials Science
- Endocrinology
Background:
- The "fully synthetic pancreas" aims for closed-loop insulin therapy by creating glucose-responsive drug delivery formulations.
- Current strategies for glucose sensing in formulations include enzymatic sensing, natural glucose-binding proteins, and synthetic molecular recognition.
Purpose of the Study:
- To highlight examples of different glucose-sensing strategies for smart insulin delivery.
- To discuss the challenges and potential impact of developing a fully synthetic pancreas.
Main Methods:
- Review and categorization of existing glucose-sensing approaches for insulin delivery formulations.
- Identification of key challenges hindering the clinical translation of these technologies.
Main Results:
- Three main categories of glucose-sensing strategies were identified: enzymatic, natural protein-based, and synthetic recognition-based.
- Significant challenges persist, including response time, glycemic control accuracy, material biocompatibility, and ensuring safety and efficacy.
Conclusions:
- Realizing a fully synthetic pancreas for diabetes management holds immense therapeutic potential.
- Overcoming challenges in sensing, delivery, and material science is crucial for advancing closed-loop insulin therapy.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
216
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
216
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
945
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
945
01:23Modified-Release Drug Delivery Systems: Classification
256
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
256
01:24Modified-Release Drug Delivery Systems: Site-Targeted
109
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
109
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
946
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
946